Oscar Health (OSCR) Stock Forecast & Price Target

Oscar Health is supported by improving underwriting discipline, with 2026 risk adjustment payable guidance revised to a midpoint of (17.5%) and MLR improved to 81.0%, while management also raised expected earnings from operations by $100 million to $600 million-$800 million. Its technology-driven platform is helping scale the business through stronger share capture, lower SG&A leverage, and automation, with total revenue guided at $18.7 billion-$19.0 billion and operating margins expected to trend toward 5% in 2027. The bullish case is reinforced by a long runway in the ACA market, where total individual enrollment is expected to grow to about 23 million lives by 2029, while Oscar aims to expand footprint and monetize adjacent opportunities beyond core insurance.

Oscar Health is facing a tougher fundamental setup because its 14.0% weighted average rate increase for CY27 appears designed to offset flat 17.0M Individual ACA enrollment from Dec-26 to Feb-27, followed by normal market contraction that could leave Dec-27 enrollment at only 13.9M to 15.4M lives. The expected decline in market-wide lives means maintaining its current 2.5M members would require materially higher share, while the outlook also depends on uncertain morbidity, metal-tier mix shifts, and post-subsidy behavior that could pressure MLR and margins. In addition, adverse selection, aggressive competition, and stricter ACA scrutiny create execution risk, so even with tech-driven growth potential, the path to profitability recovery looks less certain.